Aristeia Capital LLC cut its stake in shares of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) by 31.6% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 64,800 shares of the company’s stock after selling 30,000 shares during the period. Aristeia Capital LLC’s holdings in Pacira Pharmaceuticals were worth $2,958,000 at the end of the most recent reporting period.
A number of other institutional investors also recently added to or reduced their stakes in PCRX. Stonepine Capital Management LLC acquired a new position in Pacira Pharmaceuticals during the 3rd quarter worth approximately $14,089,000. Epoch Investment Partners Inc. increased its holdings in Pacira Pharmaceuticals by 195.7% during the 3rd quarter. Epoch Investment Partners Inc. now owns 535,999 shares of the company’s stock worth $20,127,000 after purchasing an additional 354,728 shares during the last quarter. Consonance Capital Management LP increased its holdings in Pacira Pharmaceuticals by 16.1% during the 4th quarter. Consonance Capital Management LP now owns 1,602,334 shares of the company’s stock worth $73,147,000 after purchasing an additional 222,200 shares during the last quarter. HealthCor Management L.P. increased its holdings in Pacira Pharmaceuticals by 8.6% during the 4th quarter. HealthCor Management L.P. now owns 2,800,000 shares of the company’s stock worth $127,820,000 after purchasing an additional 221,960 shares during the last quarter. Finally, Two Sigma Advisers LP increased its holdings in Pacira Pharmaceuticals by 918.8% during the 4th quarter. Two Sigma Advisers LP now owns 221,076 shares of the company’s stock worth $10,092,000 after purchasing an additional 199,376 shares during the last quarter.
In other news, CEO David M. Stack sold 28,885 shares of the business’s stock in a transaction that occurred on Wednesday, January 10th. The stock was sold at an average price of $40.19, for a total value of $1,160,888.15. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 6.60% of the stock is currently owned by insiders.
Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings results on Wednesday, February 28th. The company reported $0.38 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.08) by $0.46. Pacira Pharmaceuticals had a negative return on equity of 8.55% and a negative net margin of 14.87%. The business had revenue of $79.08 million during the quarter, compared to the consensus estimate of $79.06 million. During the same period in the previous year, the business earned $0.09 EPS. The business’s quarterly revenue was up 8.5% on a year-over-year basis. sell-side analysts predict that Pacira Pharmaceuticals Inc will post -0.24 earnings per share for the current fiscal year.
Several research firms have issued reports on PCRX. Zacks Investment Research upgraded Pacira Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, March 6th. BMO Capital Markets dropped their price objective on Pacira Pharmaceuticals from $32.00 to $31.00 and set a “market perform” rating on the stock in a report on Thursday, March 1st. Royal Bank of Canada set a $44.00 price objective on Pacira Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, March 1st. HC Wainwright set a $45.00 price objective on Pacira Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, March 1st. Finally, Oppenheimer restated a “hold” rating on shares of Pacira Pharmaceuticals in a report on Thursday, March 1st. Three research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and eight have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $45.29.
TRADEMARK VIOLATION WARNING: This piece of content was originally posted by Ticker Report and is owned by of Ticker Report. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3256639/aristeia-capital-llc-sells-30000-shares-of-pacira-pharmaceuticals-inc-pcrx.html.
Pacira Pharmaceuticals Profile
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.
Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira Pharmaceuticals Inc (NASDAQ:PCRX).
Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.